Efficacy and Safety of Shengmai Injection for Chronic Heart Failure: A Systematic Review of Randomized Controlled Trials

Table 1

Characteristics of included studies.

Author	Sample (T/C)	Age (T/C, year)	Male (T/C, %)	Course of disease (year)	Cardiac function grade (T/C)			Dose of shengmai injection	Basic treatment	Outcomes
					II	III	IV
Chen and Wang 2010 [29]	50/50	56.5/47.8	62/68	—	8/10	37/34	5/6	60 ml, q.d, 2 weeks	Diuretics, ACEI, β-blockers, CG	1, 2, 3, 4, 5
Chi 2017 [30]	40/40	63.1	57.5/67.5	9.4	17	45	18	50 ml, q.d, 4 weeks	Diuretics, ARB, β-blockers, CG	1, 2, 8
Ding 2012 [23]	40/40	70.7/72.6	45/37.5	8.70/8.9	—	30/31	10/9	40 ml, q.d, 1 week	Diuretics, ACEI, ARB, β-blockers, CG, nitroglycerin	2, 3, 4, 8
Dou 2010 [31]	30/23	66.5/67.1	60/61	8.5/7.4	10/7	16/10	4/6	100 ml, q.d, 4 weeks	ACEI, β-blockers, CG	2, 7
Kong and Zhu 2004 [32]	30/20	59/58	60/55	17/16	9/7	15/10	6/3	30 ml, q.d, 2 weeks	Diuretics, ACEI, CG,	1, 2, 4, 5
Lai 2018 [22]	65/65	61.6/65.1	65/68	11.3/12	24/21	25/25	16/15	100 ml, q.d, 1 week	ACEI, β-blockers, CG	2, 3, 4, 5, 6, 7, 8
Ni 2012 [33]	43/41	<80	—	2	—	—	—	50 ml, q.d, 2 weeks	Diuretics, ACEI, β-blockers, CG, nitroglycerin	1, 2, 6, 8
Pan 2013 [34]	34/34	63.5	82/88	2	32	36	—	60 ml, q.d,2 weeks	β-Blockers, CG, phentolamine	1, 2, 3, 4, 5
Pan 2014 [35]	21/21	59.3/56.9	90/61	2	—	—	—	50 ml, q.d, 2 weeks	Diuretics, ACEI, β-blockers, nitroglycerin, CG	1
Shi 2001, et al. [36]	82/41	65.6/64.5	57/56	10.2/9.7	19/9	41/20	22/12	100 ml, q.d, 2 weeks	Diuretics, CG, nitroglycerin, antiarrhythmic medicines	1, 3, 4, 5, 8
Sun 2013 [37]	30/30	61.4/60.5	63/60	5.92/5.5	—	—	—	60 ml, q.d, 2 weeks	Diuretics, ACEI, β-blockers, CG, isosorbide dinitrate	1, 2, 3, 4, 5
Wang 2010 [38]	41/41	63.6/64.3	63/39	5.8/6.2	14/15	21/20	6/5	40 ml, q.d, 2 weeks	Diuretics, β-blockers, CG	1, 2
Wen 2013 [39]	32/32	61/64	56/53	8.5/9	—	18/14	14/15	50 ml, q.d, 2 weeks	Diuretics, ACEI, β-blockers, CG, nitroglycerin	1, 2, 3, 4, 5, 8
Wu 2013 [40]	30/22	62/61.5	60/68	10.5/8	10/7	17/13	3/2	60 ml, q.d, 2 weeks	Diuretics, ACEI, β-blockers, CG	1, 2
Wu 2014 [41]	30/30	61.8/61.3	43/47	2.75	7/7	19/20	4/3	40 ml, q.d, 2 weeks	Diuretics, ACEI, ARB, β-blockers, CG, nitroglycerin	2, 7
Xu 2004 [42]	50/26	62/62.5	56/73	5.6/5.8	—	32/17	18/9	100 ml, q.d, 4 weeks	ACEI, CG, β-blockers	1, 2, 3, 4, 5, 8
Ye 2011 [43]	30/30	62/64	60/53	10/10	—	19/18	11/12	40 ml, q.d, 2 weeks	Diuretics, ACEI, β-blockers, CG, nitroglycerin	2, 3, 4, 5, 8
Yuan 2011 [44]	89/89	45–74	72/83	8	74	66	49	50 ml, q.d, 3 weeks	Diuretics, ACEI, β-blockers,	1, 2
Zhai 2009 [45]	30/30	62/63	60/53	10/10	—--	17/18	13/12	40 ml, q.d, 2 weeks	Diuretics, ACEI, β-blockers, nitroglycerin, CG	1, 2, 3, 4, 5, 8
Zou 2011 [46]	30/30	67.4/64.3	63/70	4.5/4.8	7/8	14/12	9/10	40 ml, q.d, 2 weeks	Diuretics, ACEI, β-blockers, CG	1, 2, 3, 4, 5

Both patients in the shengmai injection and control group received the same basic treatment in all individual randomized controlled trials. T = treatment; C = control; ACEI = angiotensin-converting enzyme inhibitors; ARB = angiotensin receptor blockers; CG = cardiac glycosides. 1: clinical efficacy; 2: left ventricular ejection fractions; 3: stroke volume; 4: cardiac output; 5: cardiac index; 6: brain natriuretic peptide; 7 : six min walk test; 8: adverse events.